Vandermeersch Sophie, Stefanovic Vadislav, Hus-Citharel Annette, Ardaillou Raymond, Dussaule Jean-Claude, Chansel Dominique
Inserm 489, Hôpital Tenon, Paris, France.
Nephron Exp Nephrol. 2003;95(3):e119-28. doi: 10.1159/000074328.
Chronic inhibition of nitric oxide synthase promotes renin-dependent hypertension and renal injury. The present study examines how renal angiotensin II receptors are expressed in this model. N(G)-nitro-L-arginine methyl ester (L-NAME) was given orally to rats for 1 month and was associated or not with captopril during the 4 last days of the administration. 125I-[Sar1, Ile8]-Ang II binding, AT1)mRNA and cytosolic calcium were studied in isolated glomeruli from L-NAME and control rats and in cultured mesangial cells from normal rats. Renal injury was marked in rats receiving L-NAME. Type I angiotensin II (AT1) receptor number and mRNA expression were decreased (p < 0.05) in glomeruli isolated from L-NAME-treated rats compared with controls, unless they received captopril in combination. The low level of AT1 receptor expression was associated with an attenuated rise of cytosolic calcium in response to angiotensin II. Angiotensin-converting enzyme activity in glomeruli and angiotensin II concentration in renal cortex were increased (p < 0.05) in rats receiving L-NAME alone, whereas aminopeptidase A activity was not modified. To better discriminate between the direct and indirect effects of nitric oxide deficiency, rat mesangial cells were exposed or not for 24 h to S-nitroso-N-acetyl penicillamine, a nitric oxide donor. Angiotensin II binding, AT1 mRNA expression and calcium response to angiotensin II were decreased in presence of the nitric oxide donor (p < 0.01). These results suggest that the decrease of AT1 receptor expression after 1 month of L-NAME treatment does not depend on a direct effect of nitric oxide deficiency but results from the high local angiotensin II concentration due to the stimulated angiotensin-converting enzyme activity. They also show that the renin-angiotensin dependence of this model of hypertension does not result from the overexpression of AT1 receptors.
一氧化氮合酶的慢性抑制会促进肾素依赖性高血压和肾损伤。本研究探讨了在该模型中肾血管紧张素II受体是如何表达的。将N(G)-硝基-L-精氨酸甲酯(L-NAME)口服给予大鼠1个月,并在给药的最后4天与卡托普利联合或不联合使用。对L-NAME处理的大鼠和对照大鼠分离出的肾小球以及正常大鼠培养的系膜细胞进行125I-[Sar1,Ile8]-Ang II结合、AT1 mRNA和细胞溶质钙的研究。接受L-NAME的大鼠出现明显的肾损伤。与对照组相比,从接受L-NAME处理的大鼠分离出的肾小球中I型血管紧张素II(AT1)受体数量和mRNA表达降低(p<0.05),除非它们联合使用卡托普利。AT1受体表达水平低与对血管紧张素II反应时细胞溶质钙升高减弱有关。单独接受L-NAME的大鼠肾小球中的血管紧张素转换酶活性和肾皮质中的血管紧张素II浓度升高(p<0.05),而氨肽酶A活性未改变。为了更好地区分一氧化氮缺乏的直接和间接影响,将大鼠系膜细胞暴露于一氧化氮供体S-亚硝基-N-乙酰青霉胺24小时或不暴露。在一氧化氮供体存在的情况下,血管紧张素II结合、AT1 mRNA表达和对血管紧张素II的钙反应降低(p<0.01)。这些结果表明,L-NAME处理1个月后AT1受体表达的降低并不取决于一氧化氮缺乏的直接作用,而是由于血管紧张素转换酶活性受刺激导致局部血管紧张素II浓度升高所致。它们还表明,该高血压模型的肾素-血管紧张素依赖性并非由AT1受体的过度表达引起。